Tumour microenvironment (TME)

#Cancer research #Oncology #T cell #Tumour biology #Tumour microenvironment (TME)

The missing link in treating cancer

Eden Ben, CEO of Amorphical, and Dr Yigal Blum, CTO of Amorphical, argue that targeting the hostile tumour microenvironment is the key to effectively treating this aggressive cancer.  For years, the conversation around pancreatic cancer has focused on the tumour itself, the "broken" cells that won't stop growing. In 2026,… Read More

#Exclusive Content

#Allergy #Biomarkers #Biotech #Breast cancer #Europe #HER2 #Immune cells #Neurology #Oncology #Pancreatic cancer #Parkinson's #Therapeutic targets #Tokyo University of Science #Tumour microenvironment (TME) #UK government

DDW Highlights: 3 February 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week’s discoveries into Parkinson’s disease, allergies and common cancers could shape drug development. Elsewhere,… Read More

#Podcasts

#Allergy #Biomarkers #Biotech #Breast cancer #Europe #HER2 #Immune cells #Neurology #Oncology #Pancreatic cancer #Parkinson's #Therapeutic targets #Tokyo University of Science #Tumour microenvironment (TME) #UK #UK government

This week in Drug Discovery (26 – 30 January) 

News round-up for 26 – 30 January by Bruno Quinney, Content Team at DDW.  This week in DDW, discoveries into Parkinson’s disease, allergies and common cancers could shape drug development. Elsewhere, why is the UK leading Europe’s biotech market? The top stories:    Parkinson’s could be identified in… Read More

#News

Pancreatic cancer
#Oncology #Pancreatic cancer #Tokyo University of Science #Tumour microenvironment (TME)

Potential tumour-suppressing gene identified in pancreatic cancer

A new study has revealed that low levels of CTDNEP1 may drive early and deadly pancreatic tumours, highlighting its role as a tumour suppressor.  Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer and begins in the cells lining the pancreatic duct. Accounting for… Read More

#Cancer Research #News

Tumour microenvironment
#Cancer #Drug development #Tumour microenvironment (TME) #Whitepaper

Whitepaper: How protein biomarkers can impact cancer outcomes

Download this whitepaper by Standard BioTools to learn about the tumour microenvironment (TME) and the protein biomarkers helping to shape cancer outcomes. The tumour microenvironment (TME) is no longer considered a passive backdrop to cancer. It is a dynamic ecosystem that plays a central role in tumour growth, immune suppression,… Read More

#News

Cancer cells
#Cancer #Cancer biology #Oncology #Tumour microenvironment (TME)

Microenvironment switches cancer cells to a drug-resistant state  

A new study has revealed that the mechanical environment surrounding a tumour can cause cancer cells to change their behaviour, triggering a switch from rapid growth to a more invasive, drug-resistant state.  Traditionally, epigenetic changes have been thought to arise from internal cellular processes, such as histone… Read More

#News

The extracellular matrix
#Barts Institute #Oncology #The Institute of Cancer Research #Tumour microenvironment (TME)

Cancer breakthrough could stop tumours before they metastasise

Scientists have discovered a new way to predict which tumours will become aggressive before they metastasise and spread around the body.  The research, published in Nature Communications, reveals how cancer cells are altered by their surroundings, enabling them to change their… Read More

#Cancer Research #News #Trending News

The tumour microenvironment
#Chemotherapy-resistance #Drug resistance #Oncology #The Institute of Cancer Research #Tumour microenvironment (TME)

Study reveals role of the secretome in cancer drug resistance

A new study has shown that non-cancerous cells positioned close to tumours can affect how cancer responds to treatment.   The researchers say factoring in the effects of these cells could improve drug development and provide new insights into the most effective use of existing cancer medications. … Read More

#Cancer Research #Editor's Choice #News

Liver cancer
#Colorectal cancer #ETH Zurich #Liver cancer #Oncology #Tumour microenvironment (TME)

Study reveals how cancer cells metastasise to the liver

Researchers at ETH Zurich in Switzerland have uncovered how colorectal cancer cells colonise the liver. The findings, by Andreas Moor in the Department of Biosystems Science and Engineering and his team, will help to develop treatments with which they hope could hinder the metastatic process. Read More

#Cancer Research #News #Trending News

Peptide
#Cancer research #HBC Immunology #Oncology #Peptides #Prostate cancer #Seed funding #Tumour microenvironment (TME)

Start-up to study peptides that modulate gene expression

HBC Immunology (a subsidiary of Hofseth BioCare) has secured seed capital financing of approximately $900,000 from external investors to commence preclinical animal trials with its patented peptides, FT-002 and FT-005. These are analogues of peptides discovered by HBC in ProGo bioactive peptides, which modulate iron metabolism… Read More

#News #Start-up Zone

#Cancer research #Macomics #Macrophages #Omics #Oncology #Tumour microenvironment (TME) #Turning Science into Business

Turning science into business: Exploiting macrophage biology

DDW’s Diana Spencer chats to Macomics’ co-founder and VP Immunology Dr Luca Cassetta about the company’s approach to tumour suppression and the challenges of launching a new business in early 2020. DS: Congratulations on the publication of your discoveries in Nature Reviews Cancer. Your studies focus on tumour associated macrophages (TAMs). What role do they… Read More

#Cancer Research #Exclusive Content

T cells attack cancer cell
#AACR 2023 #Cancer research #Melanoma #Oncology #Purple Biotech #Tumour microenvironment (TME)

New drug could help overcome tumour resistance to treatment

New study results have demonstrated the potential of a new drug to reprogramme the immune profile in the tumour microenvironment (TME) and convert resistant tumours to responders to Immune Checkpoint Blockage (ICB) therapies. Purple Biotech shared the new results at the American Association for Cancer Research… Read More

#Cancer Research #News

Macrophage
#AACR 2023 #Cancer research #Macomics #Macrophages #Oncology #Tumour microenvironment (TME)

Benefits of reprogramming tumour macrophages presented at AACR

UK company Macomics presented data demonstrating its Enigmac macrophage drug discovery platform at the American Association for Cancer Research’s Annual Meeting (AACR) in Florida. The company uses macrophage-based approaches to develop novel precision medicines to target disease specific macrophage biology. Macrophages are key players… Read More

#Cancer Research #News

Pancreatic cancer
#Cancer research #Oncology #Pancreatic cancer #Propanc Biopharma #Solid tumours #Spain #Tumour microenvironment (TME)

Proenzyme suppresses TGF-β pathway in pancreatic cancer

A Spanish study has shown that PRP, a mixture of two proenzymes, trypsinogen and chymotrypsinogen, suppresses the TGF-β pathway and the tumour microenvironment in pancreatic cancer. The study was co-led by Belén Toledo Cutillas, at the laboratory of Professor Macarena Perán, University of Jaén, Granada, Spain. Read More

#Cancer Research #Editor's Choice #News

Macrophage
#Cancer research #Immunology #Macomics #Mass spectrometry / NMR #Oncology #Transcriptomics #Tumour biology #Tumour microenvironment (TME)

Scottish company will target macrophages to treat cancer

Newly published discoveries have revealed possibilities for the treatment of cancer by targeting tumour-associated macrophages (TAMs) in the tumour microenvironment (TME).  The founding scientists behind Edinburgh-based Macomics, Dr Luca Cassetta and Professor Jeff Pollard, detail the seminal discoveries in macrophage biology over the past 50 years in… Read More

#Cancer Research #News